For inquiries or customized services, please reach us at pr@pharmaceutical-era.com
Aileron Therapeutics, Inc. a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications,...
Eisai Saudi Arabia was established in April 2024 in order to build an in-house sales system. Japan-based Eisai Co. has announced that fully-fledged operations and business activities have begun at...
Blue Earth Therapeutics Ltd, an emerging leader in the development of therapeutic radiopharmaceuticals, today announced further positive developments for its novel investigational radioligand...
Prendio-BioProcure, a leader in procurement solutions for the life science industry, is excited to launch PrendioPay, an integrated payment platform that evolves the operational reality that most...
Hansa Biopharma AB, announced positive results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487, the Company's next generation immunoglobulin G (IgG)-cleaving molecule,...
Bruker Corporation announced the acquisition of Dynamic Biosensors GmbH, a pioneering company known for its breakthroughs in biosensor development, which is based in Munich,...
Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, today unveils the new GloMax® Galaxy...
BioCare, a leader in specialty pharmaceutical distribution, is excited to announce its new partnership with AeroSafe Global, a pioneer in reliable, sustainable cold chain...
LenioBio, the leader in rapid cell-free protein expression technologies, is pleased to announce a collaboration with ReciBioPharm, a global contract development and manufacturing organization...
The ISCT Institute of Training & Development, a division of the International Society for Cell and Gene Therapy (ISCT), has become the first cell and gene therapy (CGT) organization to receive...
Repare Therapeutics Inc. a leading clinical-stage precision oncology company, reported data highlighting the clinical benefits of camonsertib, a potential best-in-class oral small molecule ATR inhibitor,...
Zhejiang Doer Biologics Co., Ltd. a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, announces that DR10624, its first-in-class...